Non-Small Cell Lung Cancer Market Size, Share, Trends, & Industry Analysis Report By Type, By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, and Others), By Distribution Channel, and By Region

Description

List of Tables

The non-small cell lung cancer market size is expected to reach USD 129.88 Billion by 2034, according to a new study by Polaris Market Research. The report "Non-Small Cell Lung Cancer Market Share, Size, Trends, Industry Analysis Report: By Type, By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, and Others), By Distribution Channel, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Non-small cell lung cancer (NSCLC) represents the majority of global lung cancer cases and is driving advances in precision oncology. Increasing use of biomarker testing, targeted therapies, and immunotherapies is reshaping treatment approaches, while innovations in liquid biopsy and mutation-specific drugs are enabling earlier diagnosis and better outcomes.

Market growth is primarily driven by the rising global incidence of NSCLC, increasing adoption of targeted and immune-based therapies and the growing availability of companion diagnostics that support personalized treatment plans.

Non-Small Cell Lung Cancer Market Report Highlights

Based on type, the adenocarcinoma segment dominated the market share in 2024, driven by its high prevalence and strong response to targeted therapy options.

In terms of treatment, the targeted therapy segment dominated the market in 2024, supported by the broad clinical use of EGFR, ALK, and KRAS inhibitors.

Based on distribution channel, the hospital pharmacy segment dominated the market in 2024, due to centralized access to advanced oncology drugs and clinical oversight.

North America accounted for the majority share in the global non-small cell lung cancer market in 2024, driven by early adoption of molecular diagnostics and regulatory support for novel therapies.

Asia Pacific is projected to grow at the fastest CAGR during the forecast period, owing to rising cancer incidence, expanding healthcare access, and growing investment in oncology research.

A few global key market players include Roche Holding AG, AstraZeneca PLC, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Eli Lilly And Company, Novartis AG, Johnson & Johnson, Amgen Inc., Beigene Ltd., Exelixis Inc., and Mirati Therapeutics Inc.

Polaris Market Research has segmented the market report on the basis of type, treatment, distribution channel, and region:

By Type Outlook (Revenue, USD Billion, 2020-2034)

Squamous Cell Carcinoma

Large Cell Carcinoma

Adenocarcinoma

Other Type

By Treatment Outlook (Revenue, USD Billion, 2020-2034)

Chemotherapy

Targeted Therapy

Immunotherapy

Others

By Distribution Channel Outlook (Revenue, USD Billion, 2020-2034)

Hospital Pharmacy

Drug Store and Retail Pharmacy

Online Pharmacy

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

Canada

Europe

Germany

France

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Product Code: PM6101

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Non-Small Cell Lung Cancer Market Insights

4.1. Non-Small Cell Lung Cancer Market - Market Snapshot
4.2. Non-Small Cell Lung Cancer Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Rapidly Rising Cases of NSCLC Globally
  - 4.2.1.2. Increasing Clinical Adoption of Liquid Biopsies and Multiplexed Testing Platforms
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. High Costs Associated with Advanced Diagnostic Tools
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Non-Small Cell Lung Cancer Market Trends
4.6. Value Chain Analysis

5. Global Non-Small Cell Lung Cancer Market, by Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
5.3. Squamous Cell Carcinoma
- 5.3.1. Global Non-Small Cell Lung Cancer Market, by Squamous Cell Carcinoma, by Region, 2020-2034 (USD Billion)
5.4. Large Cell Carcinoma
- 5.4.1. Global Non-Small Cell Lung Cancer Market, by Large Cell Carcinoma, by Region, 2020-2034 (USD Billion)
5.5. Adenocarcinoma
- 5.5.1. Global Non-Small Cell Lung Cancer Market, by Adenocarcinoma, by Region, 2020-2034 (USD Billion)
5.6. Other Type
- 5.6.1. Global Non-Small Cell Lung Cancer Market, by Other Type, by Region, 2020-2034 (USD Billion)

6. Global Non-Small Cell Lung Cancer Market, by Treatment

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
6.3. Chemotherapy
- 6.3.1. Global Non-Small Cell Lung Cancer Market, by Chemotherapy, by Region, 2020-2034 (USD Billion)
6.4. Targeted Therapy
- 6.4.1. Global Non-Small Cell Lung Cancer Market, by Targeted Therapy, by Region, 2020-2034 (USD Billion)
6.5. Immunotherapy
- 6.5.1. Global Non-Small Cell Lung Cancer Market, by Immunotherapy, by Region, 2020-2034 (USD Billion)
6.6. Others
- 6.6.1. Global Non-Small Cell Lung Cancer Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Non-Small Cell Lung Cancer Market, by Distribution Channel

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
7.3. Hospital Pharmacy
- 7.3.1. Global Non-Small Cell Lung Cancer Market, by Hospital Pharmacy, by Region, 2020-2034 (USD Billion)
7.4. Drug Store and Retail Pharmacy
- 7.4.1. Global Non-Small Cell Lung Cancer Market, by Drug Store and Retail Pharmacy, by Region, 2020-2034 (USD Billion)
7.5. Online Pharmacy
- 7.5.1. Global Non-Small Cell Lung Cancer Market, by Online Pharmacy, by Region, 2020-2034 (USD Billion)

8. Global Non-Small Cell Lung Cancer Market, by Geography

8.1. Key Findings
8.2. Introduction
- 8.2.1. Non-Small Cell Lung Cancer Market Assessment, By Geography, 2020-2034 (USD Billion)
8.3. Non-Small Cell Lung Cancer Market - North America
- 8.3.1. North America: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
- 8.3.2. North America: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
- 8.3.3. North America: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.3.4. Non-Small Cell Lung Cancer Market - U.S.
  - 8.3.4.1. U.S.: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.3.4.2. U.S.: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.3.4.3. U.S.: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.3.5. Non-Small Cell Lung Cancer Market - Canada
  - 8.3.5.1. Canada: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.3.5.2. Canada: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.3.5.3. Canada: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
8.4. Non-Small Cell Lung Cancer Market - Europe
- 8.4.1. Europe: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
- 8.4.2. Europe: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
- 8.4.3. Europe: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.4. Non-Small Cell Lung Cancer Market - UK
  - 8.4.4.1. UK: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.4.2. UK: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.4.3. UK: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.5. Non-Small Cell Lung Cancer Market - France
  - 8.4.5.1. France: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.5.2. France: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.5.3. France: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.6. Non-Small Cell Lung Cancer Market - Germany
  - 8.4.6.1. Germany: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.6.2. Germany: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.6.3. Germany: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.7. Non-Small Cell Lung Cancer Market - Italy
  - 8.4.7.1. Italy: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.7.2. Italy: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.7.3. Italy: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.8. Non-Small Cell Lung Cancer Market - Spain
  - 8.4.8.1. Spain: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.8.2. Spain: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.8.3. Spain: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.9. Non-Small Cell Lung Cancer Market - Netherlands
  - 8.4.9.1. Netherlands: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.9.2. Netherlands: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.9.3. Netherlands: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.10. Non-Small Cell Lung Cancer Market - Russia
  - 8.4.10.1. Russia: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.10.2. Russia: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.10.3. Russia: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.11. Non-Small Cell Lung Cancer Market - Rest of Europe
  - 8.4.11.1. Rest of Europe: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.11.2. Rest of Europe: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.11.3. Rest of Europe: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
8.5. Non-Small Cell Lung Cancer Market - Asia Pacific
- 8.5.1. Asia Pacific: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
- 8.5.2. Asia Pacific: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
- 8.5.3. Asia Pacific: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.4. Non-Small Cell Lung Cancer Market - China
  - 8.5.4.1. China: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.4.2. China: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.4.3. China: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.5. Non-Small Cell Lung Cancer Market - India
  - 8.5.5.1. India: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.5.2. India: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.5.3. India: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.6. Non-Small Cell Lung Cancer Market - Malaysia
  - 8.5.6.1. Malaysia: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.6.2. Malaysia: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.6.3. Malaysia: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.7. Non-Small Cell Lung Cancer Market - Japan
  - 8.5.7.1. Japan: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.7.2. Japan: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.7.3. Japan: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.8. Non-Small Cell Lung Cancer Market - Indonesia
  - 8.5.8.1. Indonesia: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.8.2. Indonesia: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.8.3. Indonesia: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.9. Non-Small Cell Lung Cancer Market - South Korea
  - 8.5.9.1. South Korea: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.9.2. South Korea: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.9.3. South Korea: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.10. Non-Small Cell Lung Cancer Market - Australia
  - 8.5.10.1. Australia: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.10.2. Australia: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.10.3. Australia: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.11. Non-Small Cell Lung Cancer Market - Rest of Asia Pacific
  - 8.5.11.1. Rest of Asia Pacific: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.11.2. Rest of Asia Pacific: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.11.3. Rest of Asia Pacific: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
8.6. Non-Small Cell Lung Cancer Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
- 8.6.2. Middle East & Africa: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
- 8.6.3. Middle East & Africa: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.4. Non-Small Cell Lung Cancer Market - Saudi Arabia
  - 8.6.4.1. Saudi Arabia: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.6.4.2. Saudi Arabia: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.6.4.3. Saudi Arabia: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.5. Non-Small Cell Lung Cancer Market - UAE
  - 8.6.5.1. UAE: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.6.5.2. UAE: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.6.5.3. UAE: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.6. Non-Small Cell Lung Cancer Market - Israel
  - 8.6.6.1. Israel: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.6.6.2. Israel: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.6.6.3. Israel: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.7. Non-Small Cell Lung Cancer Market - South Africa
  - 8.6.7.1. South Africa: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.6.7.2. South Africa: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.6.7.3. South Africa: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.8. Non-Small Cell Lung Cancer Market - Rest of Middle East & Africa
  - 8.6.8.1. Rest of Middle East & Africa: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.6.8.2. Rest of Middle East & Africa: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.6.8.3. Rest of Middle East & Africa: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
8.7. Non-Small Cell Lung Cancer Market - Latin America
- 8.7.1. Latin America: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
- 8.7.2. Latin America: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
- 8.7.3. Latin America: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.4. Non-Small Cell Lung Cancer Market - Mexico
  - 8.7.4.1. Mexico: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.7.4.2. Mexico: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.7.4.3. Mexico: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.5. Non-Small Cell Lung Cancer Market - Brazil
  - 8.7.5.1. Brazil: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.7.5.2. Brazil: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.7.5.3. Brazil: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.6. Non-Small Cell Lung Cancer Market - Argentina
  - 8.7.6.1. Argentina: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.7.6.2. Argentina: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.7.6.3. Argentina: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.7. Non-Small Cell Lung Cancer Market - Rest of Latin America
  - 8.7.7.1. Rest of Latin America: Non-Small Cell Lung Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.7.7.2. Rest of Latin America: Non-Small Cell Lung Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.7.7.3. Rest of Latin America: Non-Small Cell Lung Cancer Market, by Distribution Channel, 2020-2034 (USD Billion)

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

10.1. Amgen Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
10.2. AstraZeneca PLC
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
10.3. Beigene Ltd.
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
10.4. Bristol-Myers Squibb Company
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
10.5. Eli Lilly And Company
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
10.6. Exelixis Inc.
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
10.7. Johnson & Johnson
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
10.8. Merck & Co., Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
10.9. Mirati Therapeutics Inc.
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
10.10. Novartis AG
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
10.11. Pfizer Inc.
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
10.12. Roche Holding AG
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development